Radiopharmaceutical quality control considerations for accelerator-produced actinium therapies

Diane S Abou  
*Washington University School of Medicine in St. Louis*

Patrick Zerkel  
*Washington University School of Medicine in St. Louis*

James Robben  
*Washington University School of Medicine in St. Louis*

Mark McLaughlin  
*Modulation Therapeutics*

Tim Hazlehurst  
*Modulation Therapeutics*

*See next page for additional authors*

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

Part of the *Medicine and Health Sciences Commons*

Please let us know how this document benefits you.

**Recommended Citation**

Abou, Diane S; Zerkel, Patrick; Robben, James; McLaughlin, Mark; Hazlehurst, Tim; Morse, David; Wadas, Thaddeus J; Pandya, Darpan N; Oyama, Reiko; Gaehle, Gregory; Nickels, Michael L; and Thorek, Daniel L J, "Radiopharmaceutical quality control considerations for accelerator-produced actinium therapies." Cancer Biotherapy & Radiopharmaceuticals. 37, 5. 355 - 363. (2022).  
https://digitalcommons.wustl.edu/oa_4/333
Authors
Diane S Abou, Patrick Zerdel, James Robben, Mark McLaughlin, Tim Hazlehurst, David Morse, Thaddeus J Wadas, Darpan N Pandya, Reiko Oyama, Gregory Gaehle, Michael L Nickels, and Daniel L J Thorek

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/oa_4/333
Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies

Diane S. Abou,1–3 Patrick Zerkel,1 James Robben,1 Mark McLaughlin,4 Tim Hazlehurst,4 David Morse,4–6 Thaddeus J. Wadas,7 Darpan N. Pandya,7 Reiko Oyama,1 Gregory Gaehle,1 Michael L. Nickels,1,2,* and Daniel L.J. Thorek2,3,8,9,*

Abstract

Background: Alpha-particle-emitting radiotherapies are of great interest for the treatment of disseminated cancer. Actinium-225 \(^{225}\text{Ac}\) produces four \(\alpha\)-particles through its decay and is among the most attractive radionuclides for use in targeted radiotherapy applications. However, supply issues for this isotope have limited availability and increased cost for research and translation. Efforts have focused on accelerator-based methods that produce \(^{225}\text{Ac}\) in addition to long-lived \(^{227}\text{Ac}\).

Objective: The authors investigated the impact of \(^{225}\text{Ac}/^{227}\text{Ac}\) material in the radiolabeling and radiopharmaceutical quality control evaluation of a DOTA chelate-conjugated peptide under good manufacturing practices. The authors use an automated module under identical conditions with either generator or accelerator-produced actinium radiolabeling.

Methods: The authors have performed characterization of the radiolabeled products, including thin-layer chromatography, high-pressure liquid chromatography, gamma counting, and high-energy resolution gamma spectroscopy.

Results: Peptide was radiolabeled and assessed at >95\% radiochemical purity with high yields for generator produced \(^{225}\text{Ac}\). The radiolabeling results produced material with subtle but detectable differences when using \(^{225}\text{Ac}/^{227}\text{Ac}\). Gamma spectroscopy was able to identify peptide initially labeled with \(^{227}\text{Th}\), and at 100 d for quantification of \(^{225}\text{Ac}\)-bearing peptide.

Conclusion: Peptides produced using \(^{225}\text{Ac}/^{227}\text{Ac}\) material may be suitable for translation, but raise new issues that include processing times, logistics, and contaminant detection.

Keywords: accelerator, actinium, generator, translation

1Cyclotron Facility, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.
2Department of Radiology and 3Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, Missouri, USA.
4Modulation Therapeutics, Morgantown, West Virginia, USA.
5Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
6Department of Physics and Oncologic Sciences, University of South Florida, Tampa, Florida, USA.
7Department of Radiology, University of Iowa, Iowa City, Iowa, USA.
8Department of Biomedical Engineering, Washington University, St. Louis, Missouri, USA.
9Oncologic Imaging Program, Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
*These authors contributed equally to this work.

Address correspondence to: Daniel L.J. Thorek; Department of Radiology, Washington University School of Medicine; 510 S. Kingshighway Boulevard, St. Louis, MO 63110-1010, USA
E-mail: thorekd@wustl.edu

© Diane S. Abou et al. 2022; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License [CC-BY-NC] (http://creativecommons.org/licenses/by-nc/4.0/) which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.
Introduction

Radionuclide therapy has been a pillar of nuclear medicine for over 80 years. Phosphorus-32 was first applied by Lawrence in 1938 for treatment of leukemia, followed by other agents. Notably, the use of radiodine for hyperthyroid conditions and cancer has become standard of care. Alpha-particle emitters have long been of interest for systemic applications in oncology and degenerative conditions. These charged helium nuclei deposit MeV of energy along a short path-length of only several cell diameters. Alpha-particle-emitting radionuclides localize to sites of bone turnover, and the treatment of ankylosing spondylitis using radium-224 (224Ra) had been used widely for decades. The recent approval of radium-213 (213Bi) dichloride for metastatic prostate cancer has stimulated even further interest in the field.

Molecularly specific radioimmunotherapy involves conjugation of radionuclides to targeting vectors, often antibodies or peptides. The first clinical targeted α-particle-emitting radiotherapy development by McDevitt et al. for bismuth-213 (213Bi) subsequently led to development of actinium-225 (225Ac)-conjugated antibody and small-molecule therapies. The 225Ac isotope is considered nearly ideal for antibody-targeted radiotherapy applications because the biological half-life of a full-length immunoglobulin and the physical half-life of the parent radionuclide (t1/2 = 9.92 d) are well matched.

Increased translational efforts have revealed a supply-chain constraint for access to 225Ac. Production method, i.e., elution of a thorium-229 (229Th) generator–produces several times less than the estimated need for routine clinical practice. Demand for the isotope has spurred several developmental efforts, including cyclotron, electron, or photon irradiation of radium-226 and spallation of thorium targets by high-energy protons. This latter accelerator-based approach can produce large quantities of actinium. This includes the desired 225Ac, along with an isotopic mixture of short-lived 224,226,228Ac (t1/2 < 2 d) and long-lived 227Ac (t1/2 = 21.8 year). Half-life, infrastructure requirements, and the cost and capabilities of physical separation methods preclude enrichment of the desired 225Ac. As such, the long-lived 227Ac is present in this drug formulation reagent.

227Ac decays predominantly to 223Th (t1/2 = 18.72 d) followed by 223Ra (t1/2 = 11.43 d), both of which are also alpha-particle emitters of interest for their therapeutic potential. This creates potential issues relating to radiochemical and dosimetric impact of this increasingly complex radionuclide mixture, which includes the concatenated decay progeny of both 225Ac. Studies to date have investigated the radiochemical impact of the presence of 223Th in chelate radiolabeling. At the end of bombardment, the radioisotopic impurity of 223Ac in the 225Ac material is reported to be low (0.2%–0.3%). The ratio of isotopes changes rapidly with time as the 225Ac material decays during chromatographic separation from the target thorium and coproduced isotopes, shipment, and radiopharmaceutical preparation.

Early evaluation of the radiobiological impact of the impurity is underway in preclinical and modeling studies. These and future studies are important as long-lived impurities in historical formulations of 223Ra may have contributed to incidences of treatment-induced malignancies, however, evaluation of these data is ongoing. As well, regulatory consideration regarding the handling and disposal of the chemical and biological wastes that are contaminated with this long-lived 227Ac material are a point of continuing discussion.

The authors’ interest in the present study was to investigate the implications for quality control and clinical release processing for accelerator-produced actinium used to formulate a therapeutic agent; and the application of an automated synthesis system for such a radiopharmaceutical. They report and discuss the radionuclide and radioisotopic purity impact for this material following good manufacturing processes for labeling, including an automated radiolabeling module, and a variety of analytical methods.

Materials and Methods

Radionuclides

The 229Th generator-produced 225Ac and accelerator-produced 225/227Ac sources were supplied by the United States Department of Energy. The accelerator-produced material activity was 79.2 MBq (2.1 mCi) on 07/01/2021, 1 d following purification, and subsequently evaporated and shipped as dried nitrates (Supplementary Fig. S2). The certificate of analysis for this batch indicated an estimated 0.7 MBq (20 μCi) of 227Ac contaminant, as extrapolated from measurements of previously generated material. At receipt, the material in a Wheaton vial (3.0 mL) was measured using a well-style dose calibrator (Capintec CRC25R) set on pre-calibrated 225Ac setting number (#82) with 55 MBq (1.5 mCi) of starting material (at day 7 postradiomaterial purification, 07/06/2021). A representative certificate of analysis for generator-produced material is included (Supplementary Fig. S3).

Radiolabeling

The DOTA-labeled peptide precursor was supplied by Modulation Therapeutics, Inc., (Fig. 1C). The labeling of the peptide was carried out under good manufacturing practice, within a shielded hot cell using a multifunctional automated radiosynthesis module (Trasis, AllinOne mini). The process was controlled remotely using Supervision (v.2.28 Rev. 2, Trasis). In brief, 46.6 MBq (1.27 mCi) of the source dissolved in 0.2 M HCl was loaded under vacuum in the initial vial for radiolabeling with the DOTA-conjugated precursor (200 μg) on day 5 postradiomaterial purification.

The source was transferred to the one-pot radiolabeling reactor cassette, in which the reaction occurred in Tris buffer (1 M, pH 7.2) at 85°C for 70 min in the presence of 20% v/v L-ascorbic acid at pH 6–8. The radiolabeled peptide was transferred in saline and passed through a 0.2 μm sterilizing filter, resulting in a final volume of 9.7 mL. The final radiolabeled sample was tested for sterility and presence of bacterial endotoxins.

Radio-instant thin-layer chromatography

A sample of the final drug product material (0.4 μL each) was spotted on glass-microfiber chromatography paper impregnated with a silica gel (115 mm length) and developed using 50 mM DTPA in ultrapure water. Acquisitions of 5 min were conducted at 225Ac/213Bi equilibrium (>4 h postmigration; typically 6–7 h) utilizing a radioTLC imaging system.
under default settings and analyzed using vendor software (AR-2000 and Winscan; Bioscan). Free radiometals migrated to the front and the bioactive-labeled material remained at the origin (0–50 mm).

Peptide purification and fractionation

Reverse phase high-pressure liquid chromatography (HPLC) was undertaken utilizing an Agilent system equipped with a HiCHROM Vydec 218MS C18 (4.6 × 250 mm, 5 μm) column, running with a flow rate of 1 mL/min, and a UV detection set at 220 nm. Twenty microliters of the labeled peptide was injected for analytical chromatography and fractions were collected for radiotrace determination. The total separation was performed over 35 min and fractions were collected every 1 mL. A gradient mobile phase was used consisting of HPLC grade water (Solvent A) and acetonitrile (Solvent B) both with 0.1% trifluoracetic acid.

Gradient conditions were initially 100% (A), 0% (B); 0–20 min to reach 20% (A), 80% (B); 20–20.5 min was ramped to 100% (A), 0% (B); 20.5–35 min 100% (A), 0% (B). An elution time of 11.736 min was recorded from the radiolabeled product UV spectra, and 11.779 min was identified to be the unlabeled precursor.

Gamma counting

Collected fractions from the HPLC were measured using a COBRA-2 gamma counter (Packard) after the samples had reached an equilibrium state for $^{225}$Ac (>4 h), with an energy window channel setting of 15–800 keV. Acquisitions were recorded 1 min per sample, and the counts per minute were background corrected to determine radiochemical purity defined as the integration of collected fractions 10–14 mL (containing the peptide as determined by UV-trace) over the entire collection (35 mL). Two fractions contain detectable activity, noted as fr12 and fr13, and were submitted for further analyses.

Gamma spectroscopy

A high-purity germanium (HPGe) detector was used to acquire high energy resolution spectra for isotope identification.
The cryocooled system (GEM-50195-S; Ortec) was used with samples placed 5 cm away from the detector enclosed in a 10 cm lead shield (HPLBS1; Ametek). The energy and efficiency calibrations were completed using a gamma ray source traceable to the National Institute of Standards and Technology (Eckert Ziegler Isotope Products) allowing preset calibration of each energy peak and quantification per isotope. The same sample-to-detector geometry was used to measure the HPLC collected fractions of interest and measured over 24 h. Counts were normalized to acquisition time for each gamma spectra, and the isotope quantification was conducted utilizing Gamma-Vision Software (version 8.0, Ametek) accounting for background, half-life, abundance, acquisition time correction, and normalized for each isotope recognized by the edited library.

Safety statement
Handling and evaluation of radiological materials require careful planning, infrastructure, and training. This is all the more important for high linear energy transfer emitters, as used in this work. All experiments were conducted by staff with certified Radiation Safety approvals and dose monitoring by the Washington University School of Medicine Department of Environmental Health and Safety, in approved areas. Samples were handled in either a hot cell or chemical fume hood, and characterization measurements were performed with sealed samples in appropriate and monitored areas. All samples used in this work have half-lives ≥10 d, requiring off-site storage and specialized disposal protocols handled by Radiation Safety.

Results
Accelerator produced $^{225}/^{227}$Ac was received for radiolabeling using a preprogrammed automated radioisynthesis module (Trasis, AllinOne mini). In brief, the system consists of a volume and time-controlled heating and mixing platform for single-pot radiolabeling of the precursor DOTA-conjugated peptide. The advantages of an automated approach include a systematic and repeatable preparation method with reduced absorbed dose to the radiochemist. In addition, the device is located within an ISO7 hot cell, thereby reducing likelihood of radiocontamination to personnel, and biocontamination to the material. The module was programmed to fully automate the benchtop synthesis used to develop the radiopharmaceutical, see Figure 1. Here, the dry $^{225}$Ac-nitrate is dissolved in dilute acid, to which antioxidant and peptide is added and heated to 85°C for 70 min. The radiolabeled material was sterilized by filtration, resulting in 9.7 mL of 200 µg of peptide (48.47 MBq) for subsequent quality control analyses.

Initial radiochemical analyses were performed at the time of radiopharmaceutical production and at day 2 postlabeling (to model time elapsed required to reach and be administered to a patient). The authors first assessed the product using radio-iTLC. Radiolabeled peptide and control (uncomplexed) source radiomaterial were spotted and developed using 50 mM DTPA. The acquisition of the paper chromatographic strip by proportional counter was carried out at >6 h postdevelopment. This time is provided for $^{225}$Ac to reach secular equilibrium; and for migrated daughters, primarily $^{211}$Fr ($t_{1/2} = 4.9$ min) and $^{213}$Bi ($t_{1/2} = 45.6$ min), to decay. The radio-iTLC analysis indicated >99% radiochemical purity, Figure 2A and B. The clinical release criterion for this radiopharmaceutical includes ≥95% RCP by radio-iTLC, which was met.

Reverse-phase HPLC was also performed, demonstrating >90% chemical purity (Fig. 2C). The early (3–5 min) fractions correspond to the low retention of free metal ions (Fig. 2D). The collected peptide fractions were gamma counted, after reaching $^{225}$Ac secular equilibrium, and a 94.2% radiochemical identity was observed. This stands in contrast to the automated radiolabeling results from thorium-229 generator produced $^{225}$Ac >95% (n ≥5; Supplementary Fig. S4), analyzed by identical methods.

They next sought to investigate the radioisotopic content of the HPLC-separated peptide to interrogate this discrepancy. High-resolution gamma spectroscopy using cryocooled HPGe was acquired at multiple time points following radiolabeling to identify the peptide-complexed radionuclides. At the earliest analyzed time point, day 2 following radiolabeling, the abundant gamma emissions from $^{211}$Fr (218 keV) and $^{213}$Bi (440 keV) are prominent (Fig. 3A). The direct detection of $^{225}$Ac itself was also observed; and was quantifiable at 188 keV (this gamma ray line is isolated from daughter contributions). The activity determined from this $^{225}$Ac peak (99508 Bq) matched that of progeny $^{213}$Bi (98086 Bq) at equilibrium (Table 1). The HPGe method was in good agreement with the dose calibrator reading of the labeled radiopharmaceutical, after compensating for the proportion of activity injected by HPLC and that collected in fractions 12 and 13.

Detailed observation also revealed the presence of $^{227}$Th in the purified radiolabeled peptide fraction at day 2. The amount measured here indicates that the $^{227}$Th present was labeled onto the conjugate at synthesis. In addition, $^{228}$Ra is not clearly detected at this early time point. This underlines successful chemical purification by HPLC of this nonlabeled rare earth metal, and the direct DOTA-peptide labeling by both $^{225}/^{227}$Ac and $^{227}$Th (Fig. 3B). The samples were reanalyzed for isotopic content at 82 and 100 d post-radiolabeling (Fig. 3C, D).

Quantification of these isotopes’ activities is presented in Table 1, for each of the displayed gamma spectrum measurements. Direct quantification of $^{225}$Ac was not successful at later time points due to interfering gamma and X-rays.

![FIG. 2. Radiochemical Purity Analysis. (A) Radio-instant thin-layer (radio-iTLC) chromatography of $^{225}/^{227}$Ac radiolabeled peptide migrated by DTPA (50 mM). (B) Control radio-iTLC of source $^{226}/^{227}$Ac material under identical conditions. Peak analysis results show >99% radiochemical yield by radio-iTLC of (A). (C) UV-chromatogram from HPLC of the peptide postradiolabeling; DOTA-conjugated radiolabeled peptide peak at 11.7 min is detected. (D) Gamma counting of the HPLC fractionated samples, using an open, 15–800 keV, energy window. Free ions, noncomplexed, ions are detected in fractions 3–4, while the majority of the activity is associated with peptide at 12 mL. Calculation of radiochemical yield by gamma counted HPLC fractions was RCP = 94.2%. HPLC, high-pressure liquid chromatography.](image-url)
from the complex radionuclide mixture. The high-energy 440 keV of the $^{213}$Bi daughter could be cleanly assessed, and measured values at 82 and 100 d are within the error of the method as predicted from $^{225}$Ac-decay rate from the initial day 2 quantification. In contrast, the $^{227}$Th activity in the peptide fraction does not follow the predicted values for the half-life of this isotope, as it is fed by $^{227}$Ac decay.

The 256 keV line used for $^{227}$Th analysis has negligible interference from other emissions. Using the activity quantified at 100 d postradiolabeling (for which $^{227}$Th has reached >98% equilibrium with its parent), the authors calculated an initial $^{227}$Ac activity of 1514.2 Bq in the primary peptide fraction at the proposed day of injection. A further 68.1 Bq in the second largest fraction was measured, Table 2.

### Table 1. Activity (Bq) of Purified $^{225/227}$Ac-Labeled Peptide Fractions Measured Utilizing Gamma Spectrometry Acquired at Day 2, 84, and 100 Postradiolabeling

<table>
<thead>
<tr>
<th>Time postradiolabeling</th>
<th>2 d</th>
<th>84 d</th>
<th>100 d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ac-225 (Bq; 188 keV)</td>
<td>Measured: 99,508.98</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td></td>
<td>Predicted: 301.33</td>
<td></td>
<td>97.18</td>
</tr>
<tr>
<td>Bi-213 (Bq; 440 keV)</td>
<td>Measured: 98,086.32</td>
<td>213.81</td>
<td>77.58</td>
</tr>
<tr>
<td></td>
<td>Predicted: 297.02</td>
<td></td>
<td>95.79</td>
</tr>
<tr>
<td>Th-227 (Bq; 256 keV)</td>
<td>Measured: 1824.83</td>
<td>1435.5</td>
<td>1501.64</td>
</tr>
<tr>
<td></td>
<td>Predicted: 87.34</td>
<td></td>
<td>48.26</td>
</tr>
</tbody>
</table>

The predicted activities are calculated for the half-life of each radionuclide from that measured at day 2. The characteristic gamma line for Ac-225 could not be determined (n.d.) after day 2.

### Table 2. Isotopic Purity at the Time of Patient Injection (Day 2 Postlabeling) of Purified Peptide

<table>
<thead>
<tr>
<th>Activity (Bq) at day of injection</th>
<th>Ac-225</th>
<th>Ac-227</th>
<th>Isotopic purity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>fr12</td>
<td>98,086.32</td>
<td>1514.2</td>
<td>98.46</td>
</tr>
<tr>
<td>fr13</td>
<td>4304.06</td>
<td>68.1</td>
<td>98.43</td>
</tr>
<tr>
<td>Labeled-peptide</td>
<td>102,390.38</td>
<td>1582.3</td>
<td>98.46</td>
</tr>
</tbody>
</table>

HPLC fraction 12 (11–12 min, the most concentrated fraction) and fraction 13 (12–13 min, the end of the collected peak) constitute the full radiolabeled $^{225/227}$Ac-peptide content. Ac-225 was measured by HPGe at day 2; Th-227 was evaluated at 100 d postradiolabeling, reaching equilibrium with Ac-227.

HPLC, high-pressure liquid chromatography; HPGe, high-purity germanium.
resulting isotopic purity of actinium-225 (defined as the percentage of $^{225}$Ac to all actinium isotopes present) of the isolated radiolabeled peptide is 98.46%.

The time elapsed between final $^{225/227}$Ac purification from the accelerator bombarded material to the radiopharmaceutical labeling was ~ 7 d. This provides time for ingrowth of $^{227}$Ac daughters. The authors have modeled the radionuclides content using the Bateman equations, and displayed activity over time for all isotopes with a half-life greater than 9 d (Supplementary Fig. S5). The radionuclide content at the day of radiolabeling consists predominantly of $^{225}$Ac, as well as $^{227}$Ac and $^{227}$Th (which increases to the day of injection). The result is a radionuclidic purity for $^{225}$Ac of 97.8% at day 2 postlabeling, if they only consider therapeutic isotopes with a half-life greater than 9 d. These data demonstrate the importance of timing both between source purification and radiopharmaceutical administration, as well as controlling the molecular contents of the prepared material.

**Discussion**

Targeted radiotherapy is an emerging paradigm for the treatment of refractory and disseminated disease. Recent approvals by the European Medicines Agency and the US Food and Drug Administration (FDA), including iodine-131 ($^{131}$I) meta-iodobenzylguanidine, radium-223 ($^{223}$Ra) dichloride, and lutetium-177 ($^{177}$Lu) octreotide, are poised to be the beginning of a trend that will likely see radiotherapies become commonplace in cancer care. These treatments can be considered inherently more complex than many nonionizing agents as issues of handling, time of administration, disposal, and overlapping medical, pharmaceutical, and nuclear regulations must be considered. These issues are relevant both in the preclinical research and development space as well as in the sphere of clinical translation.

Actinium-225 has been evaluated as a $\alpha$-particle-emitting radionuclide for targeted radiotherapy applications for over 20 years, with active clinical assessments ongoing. The majority of the global supply for this work is $^{229}$Th-generator-produced material, limited to 20–40 GBq per year. Meeting additional supply requirements has been a focus for alternative production methods from the United States Department of Energy (DOE) and others. Large-scale production by proton bombardment using thorium targets is a promising approach. At this time, the DOE has submitted a provisional Drug Master File to FDA for evaluation of $^{225}$Ac produced through this process as an active ingredient in radiopharmaceutical drug manufacture.

Special consideration for the coproduced 21.7 year half-life $^{227}$Ac and its multiple $\alpha$-particle-emitting progeny may be required. This includes the radiochemical impact as well as dosimetry and potential radiobiological effects of the contaminants; the handling of long-lived radionuclide materials and wastes; and the long-term contamination of radiopharmaceutical equipment and patient treatment spaces.

The complex mixture of radionuclides present in both starting material and in the final radiolabeled product when using $^{225/227}$Ac sources is a potential confounder in radiopharmaceutical quality control and release. Gamma ray spectroscopy can be used to detect isotopes from the $^{227}$Ac decay chain (Fig. 2), a technique which may not be accessible at all dispensing academic or tertiary medical centers. The analytical studies undertaken in this work further sought to define differences in peptide labeled with either $^{225}$Th generator-produced or accelerator-produced material. The conventional $^{229}$Th generator-produced $^{225}$Ac passed radiopharmaceutical quality control levels (defined as $\geq$95% as assessed by radio-iTLC) through multiple radiolabeling runs.

Using $^{225/227}$Ac starting material for radiolabeling under identical, automated conditions led to similarly high (99%) yield by TLC, but a lower radiochemical purity of 94.2% by gamma counting. Further, their analysis of the radiopptide at late time points (100 d postradiolabeling) enables an accurate assessment of the $^{227}$Ac content in the labeled radiopharmaceutical. Using this information in concert with the early (2 d postradiolabeling) gamma ray spectroscopy data, they can state that $^{227}$Th is initially chelated by the peptide. A limitation of this study is that these results are derived from a single run with the $^{225/227}$Ac starting material, which is produced at this time on an infrequent schedule.

However, the authors posit that this would not significantly alter their results as multiple batches of this material have had similar isotopic properties. Additional replicates would strengthen the basis of these observations and these results motivate further testing, and an assessment of the analytical methods leveraged to determine radiopharmaceutical purity and labeling efficiency.

At this time, no standardized methods of analysis or release for clinical use of $^{225}$Ac-constructs have been put forward. Techniques developed from clinical development efforts have relied predominantly on TLC of radiolabeled material from $^{229}$Th generator-produced sources. Here, the francium-221 ($^{221}$Fr) and $^{213}$Bi daughters of $^{225}$Ac presenting reasonable distinctive gamma rays (218 and 440 keV) readable using NaI detection or by gas ionization. The authors’ analyses of the $^{225/227}$Ac material show that such systems are less well suited to deal with multiple $\alpha$-emitting radionuclides with similar emitted energies. Accelerator-produced material present higher challenges of detection.

<table>
<thead>
<tr>
<th>Radiopharmaceuticals</th>
<th>Dosing ($kBq/kg$)</th>
<th>Admin. $^{225}$Ac ($MBq/Cycle$)</th>
<th>$^{225}$Ac ($MBq/Cycle$)</th>
<th>Clinical trial identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{225}$Ac-HuM195</td>
<td>150</td>
<td>12</td>
<td>0.214</td>
<td>NCT02575963</td>
</tr>
<tr>
<td>$^{225}$Ac-PSMA617</td>
<td>100</td>
<td>8</td>
<td>0.144</td>
<td>NCT04597411</td>
</tr>
<tr>
<td>$^{225}$Ac-Peptide</td>
<td>$\leq 325$</td>
<td>$\leq 26$</td>
<td>$\leq 0.470$</td>
<td></td>
</tr>
</tbody>
</table>
due to the multiple overlapping $\alpha$-emitting daughters $^{227}$Th (236, 254 keV), $^{223}$Ra (145, 154, 270 keV), $^{211}$Pb (404 keV), and $^{211}$Bi (356 keV), limiting the capacity to clearly visualize and compute radiocontaminants.

In brief, the more complex mixture of isotopes present in the accelerator-produced material brings challenges for radiopharmaceuticals produced using $^{225/227}$Ac sources may have to take this into account for pharmacy release criteria. Implied in this statement is that QC evaluation of the radiochemical and nuclidic purity, along with the isotopic purity, may require systematic specific considerations for this material for each produced batch, including HPLC coupled with radiotracing and HPGe for release.

These data underline that purity considerations are driven by both the time of radiolabeling following the processing of the bombarded material, and the time between radiolabeling and administration. Experimentally derived expiration dates for the material may be required for radiopharmacy validation and release. Previous experience with radionuclide impurities can provide some guidance. Indium-111 (2.8 d) production results in a long-lived isomer, $^{114m}$In (49.5 d). The contaminant produces a highly abundant high-energy beta particle that can significantly contribute to blood dose for leukocyte-labeled $^{111}$In (n, $\gamma$) $^{177}$Lu reaction will contain $^{177m}$Lu (160 d).

In the treatment setting, the detectable $^{177m}$Lu may have only a minor contribution to imaging and therapy. Literature, regulatory and manufacturer direction, also exists for the handling and consideration of impurities in yttrium-90, including strontium-90 and yttrium-88, and generator breakthrough for strontium-82,85/rubidium-82, germanium-68/gallium-68, and molybdenum-99/technetium-99m among others. As such, the material should be used as quickly as possible. The beta-particle-emitting lutetium-177 (6.65 d) produced via the $^{176}$Lu (n, $\gamma$) $^{177}$Lu reaction will contain $^{177m}$Lu (160 d).

Standing-out against the historical considerations of impurities present in the radiopharmaceutical formulations above is the nature of the impurities for the $^{225/227}$Ac material. These include high-energy alpha- and beta-particle emitters, concatenated decay of isotopes with long half-lives. Radiopharmaceutical evaluation incorporating accurate information of the $^{225/227}$Ac, $^{227}$Th, and $^{223}$Ra and daughters in a formulation is thus necessary to fully evaluate the pharmacokinetic and dosimetric aspects of any drug. The authors have calculated the activity of $^{227}$Ac expected for a drug administration using the radiochemical yields and purity from the present work and administered activity levels of $^{225}$Ac in ongoing and proposed trials (Table 3).

It should be noted that different radiolabeling chemistries and different times of processing which will change the produced peptide. Difference in results between radio-iTLC and gamma counting may be attributed to chemical and radiological properties of the complex radionuclide mixture. The preparation and injection times of therapies using this starting material will be important considerations in the context of radiopharmacology. These are in addition to the careful regulatory guidance required on the application, disposal, and licensing aspects, which will be necessary to a safe framework to both treat patients and to work with these long-lived contaminants.

**Disclosure Statement**

M.M., T.H., and D.M. are employees of Modulation Therapeutics Incorporated. T.J.W. and D.N.P. own intellectual property on the radiopharmaceutical. The remaining authors declare no conflicts of interest.

**Funding Information**

This work was supported, in part, by the National Institutes of Health R01CA229893, R01CA201035, and R01CA240711 and Modulation Therapeutics Incorporated.

**Supplementary Material**

Supplementary Figure S1
Supplementary Figure S2
Supplementary Figure S3
Supplementary Figure S4
Supplementary Figure S5

**References**


